Remko van Leeuwen

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

Frank van Leth, Praphan Phanuphak, Kiat Ruxrungtham et al. · The Lancet · 2004 · 683 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)

Rob Schuurman, Monique Nijhuis, Remko van Leeuwen et al. · The Journal of Infectious Diseases · 1995 · 517 citations

Life Sciences, Infectious Diseases, Microbiology +17

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

Marieke den Brinker, Ferdinand W.N.M. Wit, Pauline M. E. Wertheim-van Dillen et al. · AIDS · 2000 · 396 citations

Medicine, Infectious Diseases, Pharmacology +17

Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy

Norbert A. Foudraine, Gerrit Jan Weverling, Tom van Gool et al. · AIDS · 1998 · 194 citations

Pharmacy, Infectious Diseases, Pharmacology +17

Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One‐Year Follow‐Up of a Cohort of Human Immunodeficiency Virus Type 1–Infected Persons

Ferdinand W N M Wit, Remko van Leeuwen, Gerrit Jan Weverling et al. · The Journal of Infectious Diseases · 1999 · 179 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17